UniProt P49759 · PDB · AlphaFold · Substrate: MBP · Clone: full catalytic domainhigh-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Abemaciclib | 99.5% | 0.5% | 91.48 | 0.563 |
| 2 | Brigatinib | 99.4% | 0.6% | 82.96 | 0.513 |
| 3 | Pacritinib | 98.8% | 1.2% | 88.64 | 0.452 |
| 4 | Defactinib | 97.9% | 2.1% | 92.68 | 0.450 |
| 5 | Ceritinib | 92.1% | 7.9% | 95.44 | 0.618 |
| 6 | Palbociclib | 91.4% | 8.6% | 98.75 | 0.673 |
| 7 | Gilteritinib | 89.7% | 10.3% | 88.97 | 0.506 |
| 8 | Ponatinib | 87.8% | 12.3% | 78.23 | 0.534 |
| 9 | Sunitinib | 85.7% | 14.3% | 91.73 | 0.524 |
| 10 | Midostaurin | 81.7% | 18.3% | 78.64 | 0.500 |
| 11 | Alectinib | 80.6% | 19.4% | 95.49 | 0.651 |
| 12 | Avapritinib | 72.4% | 27.6% | 97.73 | 0.644 |
| 13 | Bosutinib | 68.3% | 31.6% | 87.22 | 0.555 |
| 14 | Capivasertib | 61.9% | 38.1% | 96.48 | 0.644 |
| 15 | Neratinib | 41.8% | 58.2% | 93.18 | 0.597 |
| 16 | Nilotinib | 39.4% | 60.6% | 96.49 | 0.765 |
| 17 | Baricitinib | 35.1% | 64.9% | 97.99 | 0.616 |
| 18 | Pirtobrutinib | 34.9% | 65.1% | 99.49 | 0.656 |
| 19 | Abrocitinib | 32.1% | 67.9% | 99.50 | 0.581 |
| 20 | Alpelisib | 31.4% | 68.6% | 97.22 | 0.720 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 5.50
- Epithelial log2(TPM+1): 5.77
- Fold change: -0.27
- Status: No significant change
High-confidence drugs
- Palbociclib — inh 91.4% · KISS 44.55
- Ceritinib — inh 92.1% · KISS 37.75
- Abemaciclib — inh 99.5% · KISS 36.84
Selectivity landscape vs inhibition on CLK1
Each point is one of the 92 approved drugs; color = inhibition % on CLK1.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…